Technology-Driven Precision Medicine Company Variantyx Secures $41.5M In Funding
02/14/22, 6:00 AM
Location
framinghamMoney raised
$41.5 million
Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in funding. The series C-2 funding round, led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.
Company Info
Location
framingham, massachusetts, united states
Additional Info
Variantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to better understand a person's genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. For more information, please visit www.variantyx.com.
Contact:DeeDee Rudenstein drudenstein@propelsc.com
SOURCE Variantyx